VRDN
$26.98-0.86 (-3.09%)
Viridian Therapeutics, Inc.
Recent News
Is It Too Late To Consider Viridian Therapeutics (VRDN) After Its 82% One-Year Surge?
If you are wondering whether Viridian Therapeutics at around US$27.84 is still offering value after a strong run, the next sections will walk through what the current price might be implying. The stock has seen mixed returns, with a 2.0% decline over the past week and a 1.6% decline over the past month, yet it sits on an 81.7% return over 1 year. This stands out against its 9.3% 3 year and 61.2% 5 year returns. Recent coverage has focused on Viridian Therapeutics as investors reassess...
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June […]